Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis B Patient with Hepatitis B Surface Antigen Loss during Lamivudine Therapy by Lee, Sun-Young et al.
INTRODUCTION
The major envelope protein of hepatitis B surface antigen
(HBsAg) which consists of 226 amino acids is coded by the
S gene (1). The common antigenic determinant epitopes of
all subtypes of HBsAg are found in ‘a’ determinant which is
between amino acids 124 to 147 (2). This important region
is considered to be within a larger antigenic area called the
major hydrophilic region (MHR), and targeted antibodies
against these epitopes are used in standard assays for HBsAg
to diagnose hepatitis B virus (HBV) infection (3). However,
we encounter some HBsAg negative chronic hepatitis B (CHB)
cases with a detectable level of HBV DNA by polymerase
chain reaction (PCR) in a clinical setting. This is defined as
occult HBV infection (4), and has been reported in 9.4% of
CHB patients (5). Usually individuals with occult HBV infec-
tion have low viremia (6). Progressive decrease in HBV load
as well as replication and various relevant mutations have been
implicated in such HBsAg negativity (7). 
Occult HBV infection has also been documented after vac-
cination or hepatitis B immunoglobulin (HBIG) therapy by
previous studies (8-13). Although the underlying mechanisms
are fully unknown yet, nucleotide substitution or deletion
of viral epitopes leading to escape from HBsAg detection has
been suggested (14). As an example, some variants of ‘a’ deter-
minant were isolated from a vaccinated person showing an
altered antigenicity of HBsAg (8, 15). As a whole, this kind
of variant HBsAg evading the known protective anti-HBs
response supports the suggestion that such mutation arise as
a result of immune pressure (9). Besides, it is also known that
polymerase with YMDD mutation results in impaired repli-
cation efficiency of virus which may also decrease the produc-
tion of HBV and escape detection (16, 17). However, no single
report has been published on variant HBsAg inducing seroneg-
ativity by YMDD mutation during lamivudine therapy. 
Here, we report a variant of the overlapping gene muta-
tions isolated from a CHB patient whose serum turned into
negative for HBsAg but positive for HBV DNA during a
long term lamivudine therapy. To the best of our knowledge,
this is the first report on occult HBV infection with YMDD
mutation during the lamivudine therapy. 
MATERIAL AND METHODS
Patient
A diagnosis of chronic hepatitis B was made clinically in
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Overlapping Gene Mutations of Hepatitis B Virus in a Chronic Hepatitis
B Patient with Hepatitis B Surface Antigen Loss during Lamivudine
Therapy
Disappearance of hepatitis B surface antigens (HBsAg) in chronic hepatitis B usually
indicates clearance of hepatitis B virus (HBV) infection. However, false HBsAg nega-
tivity with mutations in pre-S2 and ‘a’ determinant has been reported. It is also known
that YMDD mutations decrease the production of HBV and escape detection of
serum HBsAg. Here, we report overlapping gene mutations in a patient with HBsAg
loss during the lamivudine therapy. After 36 months of lamivudine therapy in a 44-yr-
old Korean chronic hepatitis B patient, serum HBsAg turned negative while HBV
DNA remained positive by a DNA probe method. Nucleotide sequence of serum
HBV DNA was compared with the HBV genotype C subtype adr registered in NCBI
AF 286594. Deletion of nucleotides 23 to 55 (amino acids 12 to 22) was identified
in the pre-S2 region. Sequencing of the ‘a’ determinant revealed amino acid substitu-
tions as I126S, T131N, M133T, and S136Y. Methionine of rtM204 in the P gene
was substituted for isoleucine indicating YIDD mutation (rtM204I). We identified a
HBV mutant composed of pre-S2 deletions and ‘a’ determinant substitutions with
YMDD mutation. Our result suggests that false HBsAg negativity can be induced
by combination of overlapping gene mutations during the lamivudine therapy. 
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a 44-yr-old Korean man. It was based on the persistent ele-
vation of serum aminotransferase levels and a positive serol-
ogy for HBsAg, HBeAg, and HBV-DNA, as detected by a
DNA probe method (Table 1). After 36 months of lamivu-
dine therapy, HBsAg became negative while HBeAg and
HBV-DNA remained positive. Qualitative serological tests
for HBsAg were performed by using standard, commercial-
ly available, microparticle enzyme immunoassays (AxSym,
Abbott Laboratories). The serum concentration of HBV DNA
was 29.3 pg/mL by using a HBV hybrid capture assay II
(Digene Corp, Gaithersburg, MD, U.S.A.). 
By using a web-based genotyping resource for viral sequ-
ences (18), a comparison was made with the published sequ-
ences of HBV genotype C subtype adr registered in GenBank
(NCBI) AF 286594. The case was finally assigned as geno-
type C and subtype adr after deducing from the amino acid
substitutions at positions 122, 127, and 160.
Methods
The nucleotide sequence of Pre-S/S region of HBV isolated
from the serum of this patient was determined. In addition,
the impact of any mutation within the ‘a’ determinant on
the antigenicity of the S protein was evaluated. We also eval-
uated the presence of YMDD mutant in this patient.
HBV DNA was extracted from 200  L of serum using a
QIAamp DNA Blood Mini Kit (Qiagen Inc, Vanencia, CA,
U.S.A.). The HBV S coding region was amplified using the
following primers; HBS-1S (5′ - CTT CAT TTT GTG GGT
CAC CA-3′ , position 2803~2822) and HBS-1AS (5′ - GCT
TCC AAT TAC ATA TCC CAT GA -3′ , position 875~897).
For direct sequencing, HBS-1S, HBS-1AS, HBS-2S (5′ -GGA
ACT CCA CCA CAT TCC AC-3′ , position 3212~3215. 1~
16) and HBS-3S (5′ -TGC CTC ATC TTC TTG TTG GTT
-3′ , position 422~442) were used. PCR was performed for
30 cycles of denaturation at 94℃for 30 sec and annealing at
55℃for 30 sec, which was followed by a final primer exten-
sion at 72℃ for 1 min. Ten  L of amplified product was
examined by 1% agarose gel electrophoresis. PCR products
were stained with ethidium bromide after gel electrophoresis.
PCR amplified HBV DNA was purified by using a QIA-
gen PCR purification kit (Qiagen Inc, Vanencia, CA, U.S.A.).
Purified DNA was treated with an ABI Prism BigDye Termi-
nator Cycle Sequencing Ready Reaction kit (Applied Biosys-
tems, CA, U.S.A.). Sequences were determined using an ABI
Prism 377 DNA sequencer (Applied Biosystems) by a bidi-
rectional sequencing method. The nucleotide sequences were
compared with the sequence of the HBV genotype C subtype
adr registered in NCBI nucleotide LOCUS AF286594. Muta-
tions were confirmed by bi-directional sequencing.
The P gene region of HBV was analysed in order to iden-
tify the YMDD mutant using a direct sequencing method.
A separate set of primers or probes were not used because the
whole sequence of pre-S, pre-S2, and S-gene overlapped with
that of P gene.
RESULTS
Identification of a pre-S2 deletion mutant
Comparing the S gene nucleotide and amino acid sequences
of HBV with the published sequence of HBV genotype C
subtype adr registered in NCBI AF 286594, the pre-S2 ampli-
fication products showed deletion from nucleotide 23 to 55
(Fig. 1). This finding was consistent with the deletion of amino
acids 12 to 22 in the pre-S2 region (Fig. 2). 
Mutations on the ‘a’ determinant
PCR amplification and sequencing analyses revealed point
mutations resulting in amino acid substitutions at the group
‘a’ determinant (Fig. 3). Nucleotide substitutions included
Anti-HBs
(mIU/mL)
HBsAg
(COI)
HBeAg 
(COI)
Anti-HBe
(COI)
HBV DNA
(pg/mL)
ALT
(IU/L)
Before lamivudine therapy 4.7 11.4 1.5 - 535 146
12 months after the therapy 7.3 35.9 9.2 - 387 533
24 months after the therapy 7.3 16.2 4.0 2.1 52.1 40
36 months after the therapy  - 3.0 10.0 2.4 29.3 130
(at the time of DNA analysis)
Table 1. Status of viral markers and serum ALT levels before and after the lamivudine therapy
COI, cut off index; -, not detected.
Fig. 1. Alignment of the sequence with HBV subtype adr in the pre-
S2 region. Comparisons of nucleotide sequences in the S region
between mutant HBV and wild type HBV (NCBI nucleotide LOCUS
AF286594) reveal the deletion of nucleotide 23 to 55 in pre-S2 gene.changes of T→G at codon 126, C→A at codon 131, T→C
at codon 133, and C→A at codon 136. These changes were
consistent with amino acid substitutions at position I126S,
T131N, M133T, and S136Y. 
YIDD mutant 
A mutation in the YMDD (tyrosine, methionine, aspartate,
aspartate) motif of the viral polymerase (reverse transcriptase
[rt]) was noticed as methionine 204 to isoleucine (rtM204I)
(Fig. 4).
DISCUSSION
In the present study, we report an overlapping gene muta-
tion in a CHB patient with non-detectable HBsAg despite
the persistent hepatitis B viremia during a long term lamivu-
dine therapy. Since a loss of HBsAg usually means the end
of viral hepatitis, we should be aware of such occult HBV
infections which might lead to confusion during the antivi-
ral therapy.
Although the molecular mechanisms of these occult HBV
infections are unresolved yet, it appears that the nondetectabil-
ity of HBsAg in serum arises from several mechanisms caused
by alterations in the structural, functional, and regulatory
regions of HBV genome resulting in HBsAg in serum below
the sensitivity of standard assays (5). Previous reports on HBsAg
negative individuals with HBV persistence have suggested
that genetic mutations in the S gene allows HBV to escape
detection by standard HBsAg assays (14, 15, 19-24). A dele-
tion in the pre-S region or disruption of the S promoter leads
to the reduced synthesis of small surface antigen and results
in the accumulation of large surface proteins in greatly dilated
smooth vesicles or in the endoplasmic reticulum (25). Large
surface protein usually assembles into long, branching, fila-
mentous particles that become trapped in the endoplasmic
reticulum and cannot be secreted in the absence of small sur-
face protein (26-28). Moreover, the accumulation of large sur-
face antigens in the cytoplasm may induce endoplasmic retic-
ulum stress, which may alter the physiology or cell biology
of the hepatocytes (28). This phenomenon is related with the
control of viral replication and the evasion of immune surveil-
lance which account for the occasional life-long persistence
of HBV infection and the discrepancy between HBV DNA
and HBsAg in serum (28). In addition, substitutions within
the ‘a’ loop can create a putative glycosylation site in mutant
HBVs which makes the antigenicity of HBsAg undetectable
(20). Taken together, these mutations in S promoter gene
and ‘a’ determinant might have destroyed the antigenicity
of HBsAg in our patient because these amino acids are essen-
tial for the display of antigenicity (3).
Recently, Chaudhuri et al. reported that two major changes,
deletion in the surface promoter region and YMDD muta-
tions in the polymerase gene, are the most common obser-
vations in occult HBV infection (5). They found 3 cases of
YMDD mutations among their 9 occult HBV infections,
but all of these 3 cases were not under antiviral therapy. There-
fore, our study is still the first report on a HBV variant with
the combination of pre-S2 deletions, ‘a’ determinant substi-
tutions, and YMDD mutation during the lamivudine ther-
apy. This combination is important because polymerase with
YMDD mutation results in impaired replication efficacy of
virus, and this further leads to decreased HBV production
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Fig. 2. Translation of the pre-S2 region open reading frame aligned
with the wild type. The heterogeneous amplication products reveal
the presence of pre-S2 deletions. An arrow indicates pre-S2 dele-
tions which is consistent with deletion of amino acids 12 to 22 in
the pre-S2 region. Small boxes indicate the locations of amino acid
substitutions within the ‘a’ determinant. 
Fig. 3. Amino acid substitution within the ‘a’ loop structure of HBsAg
protein. Sequencing revealed substitutions at position I126S, T131N,
M133T, and S136Y in the ‘a’ determinant of the S gene. Black cir-
cles represent residues with mutations while gray circles represent
cysteines. White circles represent other residues. 
Fig. 4. Nucleotide and amino acid sequences of the polymerase
gene. Methionine on rtM204 is substituted by isoleucine indicating
YIDD mutation (rtM204I). 
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and escape detection (16, 17). When this YMDD mutation
happens with S gene promoter mutations like our case, this
combination may decrease the circulating HBsAg level syn-
ergistically, making the detection of serum HBsAg impos-
sible (5). 
The limitation of our study is that we could not compare
the DNA sequence variations with those before the lamivu-
dine therapy because there was no preserved serum before
the therapy. Therefore, we could not confirm whether this
YMDD mutant existed even before the lamivudine therapy
like previous report (29) or emerged during the lamivudine
therapy. Furthermore, we could not confirm whether this
YMDD mutation occurred before other mutations or not.
In other words, it is difficult to decide whether pre-S2 dele-
tions and ‘a’ determinant substitutions are a consequence of
immune pressure created by the lamivudine therapy or just
a coincidence with the emergence of YMDD mutation during
the antiviral therapy. Further investigations with serial sam-
ples before and during lamivudine therapy are warranted.
In summary, a possible explanation regarding HBsAg loss
during a long term lamivudine therapy in our patient is the
mutations in the structural proteins consisting of pre-S2 dele-
tions and ‘a’ determinant substitutions altering the antigenic
properties synergistically with the YMDD mutation. The
emergence of these overlapping gene mutations during the
antiviral therapy should be considered significant since this
false negativity might lead to confusions during the treatment.
More cases of occult HBV infection during the antiviral ther-
apy are needed for confirmation. Not only the clinical analysis
concerning HBVs which escape detection by standard HBsAg
assays despite the persistence of HBV DNA, but also the
biological analysis should be applied in the future, so that
the pathogenesis of seronegative HBV infection during the
antiviral therapy can fully be understood.
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